JP2015503635A - フマギリン誘導体ｐｈｆ複合体の医薬品配合物 - Google Patents

フマギリン誘導体ｐｈｆ複合体の医薬品配合物 Download PDF

Info

Publication number
JP2015503635A
JP2015503635A JP2014548983A JP2014548983A JP2015503635A JP 2015503635 A JP2015503635 A JP 2015503635A JP 2014548983 A JP2014548983 A JP 2014548983A JP 2014548983 A JP2014548983 A JP 2014548983A JP 2015503635 A JP2015503635 A JP 2015503635A
Authority
JP
Japan
Prior art keywords
mixture
subunits
pharmaceutical formulation
cancer
subunit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014548983A
Other languages
English (en)
Japanese (ja)
Inventor
アクリアン、ローラ
リウ、グイ
ローウィンガー、ティモシー・ビー．
マクジリカディー、デニス
スティーブンソン、チェリ
ファン・ドゥザー、ジョン
イン、マオ
ユルコベトスキー、アレクサンドル
Original Assignee
マーサナ・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マーサナ・セラピューティクス・インコーポレイテッド filed Critical マーサナ・セラピューティクス・インコーポレイテッド
Publication of JP2015503635A publication Critical patent/JP2015503635A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
JP2014548983A 2011-12-23 2012-12-21 フマギリン誘導体ｐｈｆ複合体の医薬品配合物 Pending JP2015503635A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161580016P 2011-12-23 2011-12-23
US61/580,016 2011-12-23
US201261639654P 2012-04-27 2012-04-27
US61/639,654 2012-04-27
PCT/US2012/071477 WO2013096901A1 (en) 2011-12-23 2012-12-21 Pharmaceutical formulations for fumagillin derivative-phf conjugates

Publications (1)

Publication Number Publication Date
JP2015503635A true JP2015503635A (ja) 2015-02-02

Family

ID=48669583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548983A Pending JP2015503635A (ja) 2011-12-23 2012-12-21 フマギリン誘導体ｐｈｆ複合体の医薬品配合物

Country Status (9)

Country Link
US (1) US20130189218A1 (cg-RX-API-DMAC7.html)
EP (1) EP2794582A1 (cg-RX-API-DMAC7.html)
JP (1) JP2015503635A (cg-RX-API-DMAC7.html)
KR (1) KR20140121827A (cg-RX-API-DMAC7.html)
CN (1) CN104024236A (cg-RX-API-DMAC7.html)
IN (1) IN2014MN01488A (cg-RX-API-DMAC7.html)
TW (1) TW201332574A (cg-RX-API-DMAC7.html)
UY (1) UY34542A (cg-RX-API-DMAC7.html)
WO (1) WO2013096901A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021530462A (ja) * 2018-07-03 2021-11-11 フェネック ファーマシューティカルズ，インコーポレイテッド 無水チオ硫酸ナトリウムの製剤化
JP2024539198A (ja) * 2021-10-19 2024-10-28 同宜医藥（蘇州）有限公司 コンジュゲート薬物製剤及びその製造方法と用途

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
CA2970155A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same
JP2018506509A (ja) 2014-12-09 2018-03-08 アッヴィ・インコーポレイテッド 細胞透過性Ｂｃｌ−ｘＬ阻害剤との抗体薬物コンジュゲート
JP2019501124A (ja) 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗ｈｕＬＲＲＣ１５抗体薬物コンジュゲート及びその使用方法
US10188660B2 (en) 2015-11-30 2019-01-29 Abbvie Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
EP3432925A4 (en) 2016-03-22 2019-11-06 Bionomics Limited ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
ES2864150T3 (es) 2016-05-17 2021-10-13 Abbvie Biotherapeutics Inc Conjugados de fármacos con anticuerpos anti-cMet y métodos para su uso
WO2017210566A1 (en) * 2016-06-03 2017-12-07 Novacyte, Inc. Polymer linkers and their uses
CN116173232A (zh) 2016-06-08 2023-05-30 艾伯维公司 抗cd98抗体及抗体药物偶联物
MY199278A (en) 2016-06-08 2023-10-24 Abbvie Inc Anti-b7-h3 antibodies and antibody drug conjugates
JP2019521114A (ja) 2016-06-08 2019-07-25 アッヴィ・インコーポレイテッド 抗ｅｇｆｒ抗体薬物コンジュゲート
CN109562168A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗cd98抗体及抗体药物偶联物
JP2019524651A (ja) 2016-06-08 2019-09-05 アッヴィ・インコーポレイテッド 抗ｃｄ９８抗体及び抗体薬物コンジュゲート
PH12018502602B1 (en) 2016-06-08 2023-08-16 Abbvie Inc Anti-egfr antibody drug conjugates
CN109562190A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗egfr抗体药物偶联物
MX2018015277A (es) 2016-06-08 2019-09-06 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
KR102878895B1 (ko) 2019-05-21 2025-10-31 노파르티스 아게 Cd19 결합 분자 및 이의 용도
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
EP4010371A1 (en) 2019-08-08 2022-06-15 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
TW202134277A (zh) 2019-11-05 2021-09-16 美商再生元醫藥公司 Ｎ—端ｓｃＦｖ多特異性結合分子
EP4087657A1 (en) 2020-01-08 2022-11-16 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
US20230126689A1 (en) 2020-03-06 2023-04-27 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
JP2024512324A (ja) 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用
JP2024531915A (ja) 2021-08-05 2024-09-03 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ抗体およびその使用
TW202325733A (zh) 2021-09-03 2023-07-01 美商Ｇｏ治療公司 抗醣化-lamp1抗體及其用途
TW202328188A (zh) 2021-09-03 2023-07-16 美商Ｇｏ治療公司 抗醣化-cmet抗體及其用途
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2024258967A1 (en) 2023-06-13 2024-12-19 Synthis Therapeutics, Inc. Anti-cd5 antibodies and their uses
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
AU2008331516B2 (en) * 2007-11-28 2014-01-09 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
CA2762877A1 (en) * 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021530462A (ja) * 2018-07-03 2021-11-11 フェネック ファーマシューティカルズ，インコーポレイテッド 無水チオ硫酸ナトリウムの製剤化
JP7561325B2 (ja) 2018-07-03 2024-10-04 フェネック ファーマシューティカルズ，インコーポレイテッド 無水チオ硫酸ナトリウムの製剤化
JP2024539198A (ja) * 2021-10-19 2024-10-28 同宜医藥（蘇州）有限公司 コンジュゲート薬物製剤及びその製造方法と用途

Also Published As

Publication number Publication date
US20130189218A1 (en) 2013-07-25
CN104024236A (zh) 2014-09-03
EP2794582A1 (en) 2014-10-29
TW201332574A (zh) 2013-08-16
IN2014MN01488A (cg-RX-API-DMAC7.html) 2015-04-17
UY34542A (es) 2013-07-31
WO2013096901A8 (en) 2014-08-07
KR20140121827A (ko) 2014-10-16
WO2013096901A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
JP2015503635A (ja) フマギリン誘導体ｐｈｆ複合体の医薬品配合物
US20240307368A1 (en) Antimicrobial compositions
US11224595B2 (en) Subcutaneous delivery of poly(oxazoline) polymer conjugates
JP5491485B2 (ja) 薬理活性物質と粘膜粘着性高分子とが共有結合されたコンジュゲートの経粘膜投与に使用するための経粘膜投与剤
US8758780B2 (en) Subcutaneous paliperidone composition
US20120191039A1 (en) Carrier linked pramipexole prodrugs
US20130053405A1 (en) Carrier linked paliperidone prodrugs
JP2010504960A (ja) 水難溶性カンプトテシン誘導体のサブミクロンナノ粒子及びその製造方法
JP2015509528A (ja) ピロキシカムまたはその薬学的に許容される塩とヒアルロン酸またはその薬学的に許容される塩とを含む安定な液状の医薬組成物およびその製造方法
CA2619214A1 (en) Factor xa inhibitor inclusion complex with cyclodextrin
CN101405301A (zh) 包含与粘膜粘附聚合物共价连接的药理学活性化合物的结合物以及采用该结合物的透粘膜给予药理学活性化合物的方法
US20030236224A1 (en) Modified polysaccharides exhibiting altered biological recognition
US20170368055A1 (en) Methods for treating infections
CN111868097A (zh) 司坦唑醇与透明质酸的缀合物
JP2008509141A (ja) 非経口製剤の組織刺激を軽減させる方法及び組成物
HK1196530B (en) Antimicrobial compositions
HK1196530A (en) Antimicrobial compositions